Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

J L Wang1, D Liu, Z J Zhang

  • 1Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Insights

A novel small molecule, HA14-1, targets the Bcl-2 protein to induce apoptosis in cancer cells. This discovery offers a new chemical probe for studying programmed cell death and developing cancer therapeutics.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Bcl-2 proteins regulate apoptosis, a process crucial in diseases like cancer.
  • Previous research demonstrated that Bcl-2 binding peptides could induce apoptosis in leukemia cells.

Purpose of the Study:

  • To discover a small molecule inhibitor of Bcl-2.
  • To investigate the mechanism of action of the novel compound HA14-1.
  • To evaluate HA14-1 as a potential therapeutic agent for cancer.

Main Methods:

  • Structure-based computer screening to identify Bcl-2 ligands.
  • In vitro binding assays to confirm interaction with Bcl-2.
  • Apoptosis induction studies in human acute myeloid leukemia cells (HL-60) and mouse embryonic fibroblast cells (Apaf-1(+/+) and Apaf-1(-/-)).
  • Assessment of mitochondrial membrane potential and caspase activation (caspase-9 and caspase-3).

Main Results:

  • HA14-1, a nonpeptidic small molecule, was identified as a Bcl-2 ligand.
  • HA14-1 induced apoptosis in Bcl-2-overexpressing leukemia cells, involving mitochondrial pathway activation.
  • Apoptosis induction by HA14-1 was dependent on Apaf-1.
  • HA14-1 did not inhibit Fas-mediated apoptosis.

Conclusions:

  • HA14-1 functions as a Bcl-2 inhibitor, triggering apoptosis through Apaf-1 and caspase activation.
  • This small molecule serves as a valuable chemical probe for in vivo studies of Bcl-2-regulated apoptosis.
  • HA14-1 holds potential for the development of novel anti-cancer therapeutics.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...